Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Competition between Drug Distributors Heats Up in Zhejiang Province

publication date: Mar 24, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinopharm Group announced it will acquire Zhejiang Wenling Drug Materials, based in Taizhou, Zhejiang province. Wenling, whose yearly revenues have averaged 1.1 billion RMB ($168 million) over the past three years, generates 90% of its business by selling to hospitals. The acquisition amped up a competition in Zhejiang between Sinopharm and its chief drug rival in the drug distribution sector, Shanghai Pharmaceuticals Holding. More details....

Stock Symbols: (HK: 1099) (SHE: 601607)

Share this with colleagues:  

This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners